| 3.66 Delayed Data As of 4:00pm ET |  +0.46 / +14.38%Today’s Change | 3.01 Today|||52-Week Range 32.05 | -79.62% Year-to-Date |
| 3 Beaten-Up Biotechs -- Are They Buys? Oct 13 / MotleyFool.com - Paid Partner Content | 3 Cancer Treatment Stocks to Buy Right Now Oct 10 / MotleyFool.com - Paid Partner Content |
| Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding? Oct 11 / MotleyFool.com - Paid Partner Content | Clovis Gains Rights to Pre-Clinical Cancer Program for $12M Sep 24 / Zacks.com - Paid Partner Content |
| Previous close | 3.20 |
| Today’s open | 3.26 |
| Day’s range | 3.21 - 3.76 |
| Volume | 3,891,968 |
| Average volume (3 months) | 3,346,428 |
| Market cap | $179.0M |
| Earnings growth (last year) | +3.97% |
| Earnings growth (this year) | -6.57% |
| Earnings growth (next 5 years) | +31.35% |
| Revenue growth (last year) | +71.84% |
| P/E ratio | NM |
| Price/Sales | 9.80 |
| Price/Book | 1.18 |
| Today’s change | Today’s % change | |
|---|---|---|
| ACRXAcelRx Pharmaceutica... | +0.01 | +0.45% |
| RDHLRedhill Biopharma Lt... | +0.08 | +1.31% |
| ACSTAcasti Pharma Inc | +0.04 | +1.87% |
| NERVMinerva Neuroscience... | -0.06 | -1.40% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | -$1.89 |
| Annual revenue (last year) | $95.4M |
| Annual profit (last year) | -$368.0M |
| Net profit margin | -385.80% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Boulder, Colorado |
